NasdaqGM - Delayed Quote USD

Kymera Therapeutics, Inc. (KYMR)

33.37 +0.02 (+0.06%)
At close: April 26 at 4:00 PM EDT
33.37 0.00 (0.00%)
After hours: April 26 at 4:20 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
78,592.00
78,592.00
46,826.00
72,832.00
34,034.00
Operating Expense
244,122.00
244,122.00
208,082.00
173,362.00
80,338.00
Operating Income
-165,530.00
-165,530.00
-161,256.00
-100,530.00
-46,304.00
Net Non Operating Interest Income Expense
18,568.00
18,568.00
6,448.00
313.00
711.00
Pretax Income
-146,962.00
-146,962.00
-154,808.00
-100,217.00
-45,593.00
Net Income Common Stockholders
-146,962.00
-146,962.00
-154,808.00
-100,217.00
-54,643.00
Diluted NI Available to Com Stockholders
-146,962.00
-146,962.00
-154,808.00
-100,217.00
-54,643.00
Basic EPS
-2.52
--
-2.87
-2.09
-3.15
Diluted EPS
-2.52
--
-2.87
-2.09
-3.15
Basic Average Shares
58,365.50
--
53,933.23
47,989.02
17,349.58
Diluted Average Shares
58,365.50
--
53,933.23
47,989.02
17,349.58
Total Operating Income as Reported
-165,530.00
-165,530.00
-161,256.00
-100,530.00
-46,304.00
Total Expenses
244,122.00
244,122.00
208,082.00
173,362.00
80,338.00
Net Income from Continuing & Discontinued Operation
-146,962.00
-146,962.00
-154,808.00
-100,217.00
-45,593.00
Normalized Income
-146,962.00
-146,962.00
-154,808.00
-100,217.00
-45,593.00
Interest Income
18,764.00
18,764.00
6,624.00
488.00
826.00
Interest Expense
196.00
196.00
176.00
175.00
115.00
Net Interest Income
18,568.00
18,568.00
6,448.00
313.00
711.00
EBIT
-146,766.00
-146,766.00
-154,632.00
-100,042.00
-45,478.00
EBITDA
-143,201.00
-143,201.00
-151,655.00
-97,645.00
-43,715.00
Reconciled Depreciation
3,565.00
3,565.00
2,977.00
2,397.00
1,763.00
Net Income from Continuing Operation Net Minority Interest
-146,962.00
-146,962.00
-154,808.00
-100,217.00
-45,593.00
Normalized EBITDA
-143,201.00
-143,201.00
-151,655.00
-97,645.00
-43,715.00
12/31/2020 - 8/21/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ARVN Arvinas, Inc.
32.37
+2.44%
 
NRIX Nurix Therapeutics, Inc.
12.36
0.00%
 
APGE Apogee Therapeutics, Inc.
47.13
+2.77%
 
RVMD Revolution Medicines, Inc.
35.96
+1.78%
 
RLAY Relay Therapeutics, Inc.
6.37
+3.49%
 
PCVX Vaxcyte, Inc.
60.72
+1.10%
 
TNGX Tango Therapeutics, Inc.
7.44
+1.50%
 
SWTX SpringWorks Therapeutics, Inc.
45.53
+3.01%
 
EWTX Edgewise Therapeutics, Inc.
16.17
+1.44%
 
ITOS iTeos Therapeutics, Inc.
10.80
+1.89%